Literature DB >> 22179324

Prediction of response to androgen deprivation therapy and castration resistance in primary metastatic prostate cancer.

Rauf Taner Divrik1, Levent Türkeri, Ali F Şahin, Bülent Akdoğan, Ferhat Ateş, Çağ Çal, Sümer Baltacı.   

Abstract

PURPOSE: We tried to establish the predictive factors influencing the initial response, as well as its duration, and time to castration resistance (CR) for primary advanced prostate cancer (PC) with bone metastasis.
METHODS: We evaluated all patients initially receiving androgen deprivation therapy (ADT) for primary advanced PC with bone metastasis. A total of 982 patients with complete medical records available for analysis from 18 centers were included in this study. Age, initial PSA, Gleason score (GS) and extent of bone involvement (EBI) were recorded in a database.
RESULTS: Among all the patients, 896 (91.2%) responded to ADT initially. Pretreatment PSA and EBI were significant predictors in the multivariate model. Among the 659 patients who progressed into a CR state, the mean duration of response was 22.4 months. There was a significant correlation between the CR state and nadir PSA (nPSA) level and time to nPSA. Pretreatment PSA, EBI, GS, highest tumor volume in biopsy cores (%), number of positive biopsy cores, percent positive biopsy cores and time to nPSA were proven to be significant to predict a nPSA. Pretreatment PSA, GS and EBI were statistically significant predictors of PSA normalization in multivariate analysis. The limitation of the study depends on the retrospective design and a model was developed for low standardization as a result of using multicenter data. The patients enrolled in this study were from a relatively long period of time (1989-2008).
CONCLUSIONS: The results of this study indicate that it is possible to predict the initial response to ADT by pretreatment PSA levels and EBI, while the duration of response can be reflected by a multitude of clinical factors including nPSA, TTnPSA, percent positive cores, biopsy GS and EBI.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22179324     DOI: 10.1159/000334539

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  6 in total

1.  Impact of Time to Castration Resistance on Survival in Metastatic Hormone Sensitive Prostate Cancer Patients in the Era of Combination Therapies.

Authors:  Mike Wenzel; Felix Preisser; Benedikt Hoeh; Maria Schroeder; Christoph Würnschimmel; Thomas Steuber; Hans Heinzer; Severine Banek; Marit Ahrens; Andreas Becker; Pierre I Karakiewicz; Felix K H Chun; Luis A Kluth; Philipp Mandel
Journal:  Front Oncol       Date:  2021-04-23       Impact factor: 6.244

Review 2.  Role of miRNA let-7 and its major targets in prostate cancer.

Authors:  Siegfried Wagner; Anaclet Ngezahayo; Hugo Murua Escobar; Ingo Nolte
Journal:  Biomed Res Int       Date:  2014-09-03       Impact factor: 3.411

3.  Role of textural heterogeneity parameters in patient selection for 177Lu-PSMA therapy via response prediction.

Authors:  Zain Khurshid; Hojjat Ahmadzadehfar; Florian C Gaertner; László Papp; Norbert Zsóter; Markus Essler; Ralph A Bundschuh
Journal:  Oncotarget       Date:  2018-09-07

4.  Risk factors for progression to castration-resistant prostate cancer in metastatic prostate cancer patients.

Authors:  Ting-Ting Lin; Ye-Hui Chen; Yu-Peng Wu; Shao-Zhan Chen; Xiao-Dong Li; Yun-Zhi Lin; Shao-Hao Chen; Qing-Shui Zheng; Yong Wei; Ning Xu; Xue-Yi Xue
Journal:  J Cancer       Date:  2019-09-07       Impact factor: 4.207

5.  HMGB1: A Promising Therapeutic Target for Prostate Cancer.

Authors:  Munirathinam Gnanasekar; Ramaswamy Kalyanasundaram; Guoxing Zheng; Aoshuang Chen; Maarten C Bosland; André Kajdacsy-Balla
Journal:  Prostate Cancer       Date:  2013-05-12

Review 6.  Molecular signaling involving intrinsically disordered proteins in prostate cancer.

Authors:  Anna Russo; Sara La Manna; Ettore Novellino; Anna Maria Malfitano; Daniela Marasco
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.